These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 28101917)

  • 21. Serous surface papillary borderline ovarian tumors: correlation of sonographic features with clinic pathological findings.
    Wang D; Su N; Wang R; Zhang L; Qi Z; Liu Z; Yang J; Leng J; Xiang Y;
    Ultrasound Obstet Gynecol; 2024 May; 63(5):691-698. PubMed ID: 37592848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and ultrasound features of benign, borderline, and malignant invasive mucinous ovarian tumors.
    Pascual A; Guerriero S; Rams N; Juez L; Ajossa S; Graupera B; Hereter L; Cappai A; Pero M; Perniciano M; Errasti T; Parra J; Solis M; Alcázar JL
    Eur J Gynaecol Oncol; 2017; 38(3):382-386. PubMed ID: 29693878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fertility Preservation Is Safe for Serous Borderline Ovarian Tumors.
    Vancraeynest E; Moerman P; Leunen K; Amant F; Neven P; Vergote I
    Int J Gynecol Cancer; 2016 Oct; 26(8):1399-406. PubMed ID: 27465897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound characteristics of different types of adnexal malignancies.
    Valentin L; Ameye L; Testa A; Lécuru F; Bernard JP; Paladini D; Van Huffel S; Timmerman D
    Gynecol Oncol; 2006 Jul; 102(1):41-8. PubMed ID: 16386783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A New Insight on Exophytic Serous Borderline Adnexal Tumors: Specific Sonographic Features.
    Haddad L; Kugelman N; Shapiro I; Bakry H; Weizman B; Korobochka R; Sagie S; Said-Idris S; Bejar J; Leibovitz Z
    J Ultrasound Med; 2022 Jun; 41(6):1549-1557. PubMed ID: 34562042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early stage primary ovarian mucinous carcinoma: Outcome-based clinicopathological study in comparison with serous carcinoma.
    Tian Q; Lu B; Ye J; Lu W; Xie X; Wang X
    J Int Med Res; 2016 Apr; 44(2):357-66. PubMed ID: 26880793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
    AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging in gynecological disease (14): clinical and ultrasound characteristics of ovarian clear cell carcinoma.
    Pozzati F; Moro F; Pasciuto T; Gallo C; Ciccarone F; Franchi D; Mancari R; Giunchi S; Timmerman D; Landolfo C; Epstein E; Chiappa V; Fischerova D; Fruscio R; Zannoni GF; Valentin L; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2018 Dec; 52(6):792-800. PubMed ID: 29978567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CA 125 measurement and ultrasonography in borderline tumors of the ovary.
    Gotlieb WH; Soriano D; Achiron R; Zalel Y; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    Am J Obstet Gynecol; 2000 Sep; 183(3):541-6. PubMed ID: 10992171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
    Sans M; Gharpure K; Tibshirani R; Zhang J; Liang L; Liu J; Young JH; Dood RL; Sood AK; Eberlin LS
    Cancer Res; 2017 Jun; 77(11):2903-2913. PubMed ID: 28416487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-risk borderline ovarian tumors: analysis of clinicopathological features and prognostic impact of different follow-up strategies.
    Lorusso D; Ratti M; Ditto A; Raspagliesi F
    Oncology; 2014; 87(3):183-92. PubMed ID: 25033912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
    Feng Z; Wen H; Ju X; Bi R; Chen X; Yang W; Wu X
    J Ovarian Res; 2017 Jan; 10(1):7. PubMed ID: 28122595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnetic resonance imaging for distinguishing ovarian clear cell carcinoma from high-grade serous carcinoma.
    Ma FH; Qiang JW; Zhang GF; Li HM; Cai SQ; Rao YM
    J Ovarian Res; 2016 Jul; 9(1):40. PubMed ID: 27377917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.